News
ASCO26: Revolution's 'grand slam' data in pancreatic cancer
Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.
News
ASCO26: Big win for Erleada in perioperative prostate cancer
ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.
News
ASCO26: Ivonescimab improves survival in NSCLC
Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.
News
ASCO26: Lilly's Retevmo aces early-stage lung cancer trial
Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.
Oncology
ASCO26: AI supercharging gene-based cancer detection, with D...
Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
